Picture of Ajanta Pharma logo

AJANTPHARM — Ajanta Pharma News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

India's Ajanta Pharma falls as analysts say growth to moderate in H2

BUZZ-India's Ajanta Pharma falls as analysts say growth to moderate in H2

** Ajanta PharmaAJPH.NS shares down about 3% at 3,405.30 rupees

** Stock logs biggest pct fall in over three weeks

** Growth in Africa institutional business unlikely to sustain at similar levels in H2, says Systematix (reduces rating to "hold" from "buy", TP at 3,908 rupees)

** Co maintaining FY guidance suggests some Q2 upside could be offset by H2 weakness, says Elara Capital ("reduce", TP at 3,310 rupees)

** EBITDA margin to moderate in H2 due to US competition, normalisation of institutional sales, higher investments in R&D/field force, says Motilal Oswal ("buy", TP at 4,075 rupees)

** Q2 revenue up 32.5%, net profit up 49.2%

** 14 analysts on average rate stock "buy", median TP at 3,800 rupees—LSEG-compiled data

** YTD, shares up 15.7%


(Reporting by Saikeerthi in Bengaluru)

((Saikeerthi@thomsonreuters.com;))

Recent news on Ajanta Pharma

See all news